X4 Pharmaceuticals Inc (XFOR) — Cash Flow-to-Debt Ratio
X4 Pharmaceuticals Inc (XFOR) has a Cash Flow-to-Debt Ratio of -0.19x as of March 2026, meaning its operating cash flow of $-19.60 Million could theoretically repay 0% of its total liabilities ($101.83 Million) in one year. See working capital position of X4 Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
X4 Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for X4 Pharmaceuticals Inc across 11 annual periods. Also explore XFOR net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for X4 Pharmaceuticals Inc (2015–2025)
Year-by-year debt coverage analysis for X4 Pharmaceuticals Inc. For market capitalisation and broader financial context, see X4 Pharmaceuticals Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.82x | $-85.62 Million | $104.17 Million | ▲ +22.0% |
| 2024 | -1.05x | $-130.90 Million | $124.30 Million | ▼ -4.9% |
| 2023 | -1.00x | $-96.51 Million | $96.16 Million | ▼ -6.1% |
| 2022 | -0.95x | $-77.10 Million | $81.53 Million | ▲ +29.6% |
| 2021 | -1.34x | $-70.91 Million | $52.76 Million | ▼ -14.4% |
| 2020 | -1.17x | $-58.82 Million | $50.07 Million | ▲ +23.1% |
| 2019 | -1.53x | $-48.05 Million | $31.48 Million | ▲ +13.5% |
| 2018 | -1.76x | $-25.42 Million | $14.40 Million | ▼ -42.8% |
| 2017 | -1.24x | $-27.87 Million | $22.55 Million | ▼ -39.0% |
| 2016 | -0.89x | $-21.64 Million | $24.33 Million | ▼ -14.2% |
| 2015 | -0.78x | $-10.82 Million | $13.88 Million | — |